Date | Insider | Price | Amount |
---|---|---|---|
9-15-2021 Insider Buy |
Laurence Reid President and Chief Executive |
$7.64 CAGR » |
$76,400.00 10,000 shares |
2-17-2021 Insider Buy |
Plc Glaxosmithkline Director |
$18.00 CAGR » |
$2,700,000.00 150,000 shares |
2-17-2021 Insider Buy |
Matthew Foy Director and >10% Owner |
$18.00 CAGR » |
$2,700,000.00 150,000 shares |
2-17-2021 Insider Buy |
ORBIMED ADVISORS LLC Director and >10% Owner |
$18.00 CAGR » |
$29,999,988.00 1,666,666 shares |
Also See: Institutional Holders of DBTX
Also See: SEC filings
Growth of $10,000.00 Without Dividends Reinvested |
||
Start date: | 09/16/2021 | |
End date: | 09/25/2023 | |
Start price/share: | $8.18 | |
End price/share: | $4.91 | |
Dividends collected/share: | $0.00 | |
Total return: | -39.98% | |
Average Annual Total Return: | -22.28% | |
Starting investment: | $10,000.00 | |
Ending investment: | $6,002.97 | |
Years: | 2.02 |
DBTX Insider Buying
This Holdings Channel page has presented insider buying activity, covering Directors, officers (such as CEO, CFO, COO, etc.), and >10% owners (who are required to file form 4's with the SEC). Important institutional owners may not fall under these categories, but instead file their holdings quarterly on the latest form 13F filings. While recent DBTX insider buying activity is included, there may also be stock sales over this same period (Also See: SEC filings for sales and other details).
Also See: Funds Holding DBTX
Free DBTX Email Alerts: Get Dividend Alerts Get SEC Filing Alerts |